Difference between revisions of "Example orders for Cabazitaxel (Jevtana) in prostate cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br>  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>  Please help us by filling it out!<br>  '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth")
m (Text replacement - "font-size:200%"> Hello!<br>  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>  Please help us by filling it out!<br>" to "font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>")
Line 1: Line 1:
 
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center"  
 
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center"  
 
|
 
|
<span style="font-family:Arial; font-size:200%">&nbsp;Hello!<br>
+
<span style="font-family:Arial; font-size:300%">&nbsp;Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>
&nbsp;We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>
 
&nbsp;Please help us by filling it out!<br>
 
 
&nbsp;'''Link:''' http://j.mp/2BlBaoQ
 
&nbsp;'''Link:''' http://j.mp/2BlBaoQ
 
</span>
 
</span>

Revision as of 04:21, 23 January 2018

 Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.
 Link: http://j.mp/2BlBaoQ


Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.


Cabazitaxel (Jevtana)

Published regimens and references can be found on the prostate cancer page.

Example order set #1

21-day cycles

Supportive medications

  • Dexamethasone (Decadron) 12 mg PO once 30 minutes prior to chemotherapy
  • Diphenhydramine (Benadryl) 25 to 50 mg IV once 30 minutes prior to chemotherapy
  • Ondansetron (Zofran) 8 mg PO once 30 minutes prior to chemotherapy
  • If ondansetron not used: Prochlorperazine (Compazine) 10 mg PO/IV once 30 to 60 minutes prior to chemotherapy
  • Famotidine (Pepcid) 20 mg IV over 15 minutes once 30 minutes prior to chemotherapy
  • Pegfilgrastim (Neulasta) 6 mg SC once on day 2, 24 hours after completion of chemotherapy

Hydration:

  • Normal saline IV continuous infusion at 5 mL/H
  • Normal saline 25 to 50 mL IV prn flush before and after chemotherapy

Monitoring/precautions:

  • Notify physician if ANC <1500, AST/ALT ≥1.5 times upper limit of normal
  • Exercise caution with/avoid use of Cyp3A inducers such as phenytoin and rifampin
  • Exercise caution with/avoid use for patients with hepatic insufficiency

Nursing:

  • Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
  • Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.

Example order set #2

21-day cycles

Supportive medications

  • Dexamethasone (Decadron) 12 mg IV once 30 minutes prior to chemotherapy
  • Prochlorperazine (Compazine) 10 mg PO/IV once 30 to 60 minutes prior to chemotherapy
  • Diphenhydramine (Benadryl) 25 to 50 mg IV once 30 minutes prior to chemotherapy
  • Famotidine (Pepcid) 20 mg IV over 15 minutes once 30 minutes prior to chemotherapy
  • Due to refractory nausea/vomiting, the following were also used:
    • Ondansetron (Zofran) 8 mg IV once 30 minutes prior to chemotherapy
    • Fosaprepitant (Emend) 150 mg IV once 30 minutes prior to chemotherapy, admix with dexamethasone and ondansetron

Nursing:

  • Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
  • Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.